Medical/Pharmaceuticals

Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing

* Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) based inRiyadh. * JV focuses on providing state-of-the-art multiomic testing services to patients, health system...

2023-07-02 14:00 3294

Clinical Trial Data of Novel Metabolic Mechanism in Migraine: CER-0001, a Ketogenic Investigational Agent

* A poster showcasing data from the RELIEF study of CER-0001 (tricaprilin), being investigated for the preventive treatment of migraine, was presented at the 65th Annual Society Meeting of the American Headache Society * Data from the pilot study, showed a positive efficacy signal and supports...

2023-07-01 00:52 4149

Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at ESMO GI Annual Congress 2023

* 64 patients with CLDN18.2 positive G/GEJ cancer were enrolled in TranStar102 (TST001-1002). CLDN18.2 positivity is defined as ≥10% tumor cells with ≥1+ intensity. These patients represent approximately 55% of all G/GEJ adenocarcinomas. The overall median PFS was 9.5 months with no differences...

2023-06-30 17:33 2787

Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023

SHANGHAI, June 30, 2023 /PRNewswire/ -- Bioheart (02185.HK), together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023. Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial to evaluate the safety...

2023-06-30 11:37 2897

BGI Genomics obtains BSI ISO 37301 Compliance Management System Certification

HONG KONG, June 30, 2023 /PRNewswire/ -- As businesses become increasingly global, changes are happening at an extraordinary pace. Compliance is critical for large economies, industry regulations, and enterprise operations. BGI Genomics prioritizes compliance management and strictly follows law...

2023-06-30 08:37 3019

Cresilon Receives First FDA Clearance For Human Use of Hemostatic Gel Technology

NEW YORK, June 29, 2023 /PRNewswire/ -- Cresilon, Inc. ("Cresilon"), a Brooklyn -based biotechnology company focused on hemostatic medical device technologies, today announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for Cresilon Hemostatic Gel™ ...

2023-06-29 20:00 2121

CPHI & PMEC China 2023 to launch international roadshow in Guangzhou

China's booming Pearl River Delta, a key pharma manufacturing hub, sees rapid internationalisation SHANGHAI, June 29, 2023 /PRNewswire/ -- CPHI & PMEC China will open a special roadshow to be hosted at the PWTC Expo (4-6 September, 2023) in the city of Guangzhou (Guangdong Province). The new add...

2023-06-29 18:10 2261

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

New state-of-the-art facility to develop immunotherapy assets to address unmet needs in cancer treatment SINGAPORE, June 29, 2023 /PRNewswire/ -- Biosyngen, an immune-oncology company with technology targeting the unmet medical needs in solid tumour and lymphoma treatment, today announced the of...

2023-06-29 17:14 3513

Berlin Heals Holding AG Successfully Completes Financing Round for Ongoing CE-Study

ZUG, Switzerland, June 29, 2023 /PRNewswire/ -- Berlin Heals Holding AG, a MedTech startup, has developed a breakthrough method and a product for the therapy of heart failure. The product - an electronic device called C-MIC - has already successfully been tested in patients in a pilot study and i...

2023-06-29 17:00 2398

Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis Vaccine Candidate That Could Be the First in 100 Years If Proven Effective

TB is one of the world's deadliest diseases, killing about 4,300 people per day, mostly those living in poverty  LONDON and SEATTLE, June 29, 2023 /PRNewswire/ -- Wellcome and the Bill & Melinda Gates Foundation today announced funding to advance a tuberculosis (TB) vaccine candidate, M72/AS01E ...

2023-06-29 00:00 2912

Babies Bliss Introduces Comprehensive Fertility Wellness Programme to Enhance Reproductive Health and Conception Journey

SINGAPORE, June 28, 2023 /PRNewswire/ -- Babies Bliss, a Singapore-based fertility wellness centre, is proud to announce its innovative fertility wellness programme designed to support women in improving their reproductive health and preparing their bodies for conception. The comprehensive progra...

2023-06-28 18:44 2179

European Society of Hypertension Announces Comprehensive New Guidelines for the Management of Arterial Hypertension

MILAN, June 28, 2023 /PRNewswire/ -- The European Society of Hypertension (ESH), the leading hypertension society inEurope, released updated and expanded 2023 ESH Guidelines for the Management of Arterial Hypertension during three oral presentations atthe 32nd Annual European Meeting on Hypertens...

2023-06-28 18:00 7211

Lo.Li. Pharma International and its International Partners Achieve a New World Record to Raise Awareness About Innovative Options for Managing PCOS and Infertility

COPENHAGEN, Denmark, June 28, 2023 /PRNewswire/ -- The Society of Human Reproduction and Embryology (ESHRE) annual meeting witnessed a historic event as people from around the globe gathered both in person and online to set a new world record for the most people consuming a dose of inositol simul...

2023-06-28 17:25 2473

Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

SHANGHAI, June 28, 2023 /PRNewswire/ -- Nuance Pharma announces its partner, Verona Pharma plc (Nasdaq: VRNA),  has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of ensifentrine for the maintenance treatment of patients with chronic obstructi...

2023-06-28 17:07 3351

First Drug Discovered and Designed with Generative AI Enters Phase II Trials, with First Patients Dosed

* After completing the Phase 0 and Phase I human safety studies, INS018_055, Insilico's AI-discovered and AI-generated drug, has entered multi-regional Phase II clinical trials in the U.S andChina. * The first human patients were dosed with the drug. * This is a potentially first-in-class an...

2023-06-27 21:00 3077

TMRW Life Sciences Names Louis Villalba Chief Executive Officer

Seasoned Executive Appointed to Lead Fast-Growing Technology Company as It Signs 50 Fertility Clinics Representing Nearly 20% Market Share NEW YORK, June 27, 2023 /PRNewswire/ -- Today, TMRW Life Sciences, Inc. ("TMRW"), a fertility technology company automating the IVF lab, appointedLouis Villa...

2023-06-27 20:00 1809

Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership

SHANGHAI, June 27, 2023 /PRNewswire/ -- June 26th, 2023, Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics. As leaders in their respective...

2023-06-27 15:33 2814

Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy

SINGAPORE and GUANGZHOU, China, June 27, 2023 /PRNewswire/ -- 27 June 2023, Lion TCR, a clinical-stage T-cell immunotherapy company, is thrilled to announce the successful completion of itsUSD 40 million Series B2 financing round. Guangzhou Industrial Investment and Capital Operation Holding Grou...

2023-06-27 08:30 3066

CStone announces GAVRETO® (pralsetinib) sNDA approval by China NMPA for first-line treatment of patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer

* The approval for the first-line treatment of RET fusion-positive non-small cell lung cancer marks the third indication of GAVRETO in Mainland China, and the eleventh new drug application approval that CStone has obtained inGreater China overall. * In the ARROW study, GAVRETO had demonstrate...

2023-06-27 08:05 3023

New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC

MELBOURNE, Australia, June 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRC...

2023-06-27 03:51 2144
1 ... 9899100101102103104 ... 397

Week's Top Stories